Showing 1 - 8 results of 8 for search 'Robert A. Hauser', query time: 0.01s Refine Results
  1. 1
    Sedation and sleep safety of pimavanserin for Parkinsons’s disease psychosis: Review and exploratory analysis of clinical study data

    Sedation and sleep safety of pimavanserin for Parkinsons’s disease psychosis: Review and exploratory analysis of clinical study data by Ana Berrio, Lambros Chrones, Victor Abler, Robert A. Hauser

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    A2A Receptor Antagonism and Dyskinesia in Parkinson’s Disease

    A2A Receptor Antagonism and Dyskinesia in Parkinson’s Disease by Micaela Morelli, Fabio Blandini, Nicola Simola, Robert A. Hauser

    Published 2012-01-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    How to dose extended-release carbidopa-levodopa capsules (IPX203, CREXONT®) in patients with Parkinson’s disease

    How to dose extended-release carbidopa-levodopa capsules (IPX203, CREXONT®) in patients with Parkinson’s disease by Robert A. Hauser, Yasar Torres-Yaghi, Stanley Fisher, Ghazal Banisadr

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary®): Results of a Nationwide Dose Conversion Survey

    Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary®): Results of a Nationwide Dose Conversion Survey by Robert A. Hauser, Ghazal Banisadr, Kara Vuong, David Freilich, Stanley Fisher, Richard D’Souza

    Published 2021-01-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Abbreviated MDS-UPDRS for Remote Monitoring in PD Identified Using Exhaustive Computational Search

    Abbreviated MDS-UPDRS for Remote Monitoring in PD Identified Using Exhaustive Computational Search by Gareth Morinan, Robert A. Hauser, Anette Schrag, Jingxuan Tang, Jonathan O’Keeffe, null MDS-NMS Scale Development Study Group

    Published 2022-01-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Minimal Clinically Important Difference in Parkinson’s Disease as Assessed in Pivotal Trials of Pramipexole Extended Release

    Minimal Clinically Important Difference in Parkinson’s Disease as Assessed in Pivotal Trials of Pramipexole Extended Release by Robert A. Hauser, Mark Forrest Gordon, Yoshikuni Mizuno, Werner Poewe, Paolo Barone, Anthony H. Schapira, Olivier Rascol, Catherine Debieuvre, Mandy Fräßdorf

    Published 2014-01-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Efficacy Remaining at Time of Requested Re-Treatment for Cervical Dystonia: A Potential New Treatment Paradigm with DaxibotulinumtoxinA

    Efficacy Remaining at Time of Requested Re-Treatment for Cervical Dystonia: A Potential New Treatment Paradigm with DaxibotulinumtoxinA by Aaron Ellenbogen, Robert A. Hauser, Atul T. Patel, Peter McAllister, Todd M. Gross, Rashid Kazerooni, Conor J. Gallagher, David A. Hollander

    Published 2025-03-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Correction: Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease

    Correction: Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease by Samuel Frank, Karen E. Anderson, Hubert H. Fernandez, Robert A. Hauser, Daniel O. Claassen, David Stamler, Stewart A. Factor, Joohi Jimenez-Shahed, Hadas Barkay, Amanda Wilhelm, Jessica K. Alexander, Nayla Chaijale, Steve Barash, Juha-Matti Savola, Mark Forrest Gordon, Maria Chen

    Published 2024-09-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: